As the demand for COVID-19 vaccines wanes, the world’s largest vaccine manufacturer is shifting gears. 

The ​Serum ​Institute ​of ​India ​is repurposing ​facilities ​previously ​used for ​COVID​-​19 ​shots to ​​accelerate ​the ​production of ​new ​vaccines ​targeting ​other ​deadly ​diseases​, ​such ​as malaria ​and ​​dengue ​fever​​​.

________________________________________________________________________

• Serum Institute repurposes COVID-19 vaccine facilities to produce 2.5 billion more doses of new vaccines annually.

• New ​​vaccines ​target ​malaria ​and ​dengue ​fever​, ​​which ​kill ​over ​500​,​000 ​people ​per ​year​.

• The ​company ​​aims ​to ​export ​new ​vaccines ​globally ​​rather than ​​license production​.​​

________________________________________________________________________

Beyond COVID-19: Serum Institute Pivots to New Vaccines for Malaria and Dengue

An Interview with CEO Adar Poonawalla

In a recent interview, Serum Institute CEO Adar Poonawalla revealed that the company has boosted total vaccine production capacity by 2.5 billion doses annually. 

This comes after a $2 billion investment at the pandemic’s peak to ramp up COVID-19 vaccine manufacturing.

“We can now vaccinate India against a new pandemic in just 3-4 months,” Poonawalla stated. 

The ​company ​is ​discussing ​utilizing this ​surge capacity ​with ​other countries ​for future ​outbreaks​​​.

The Malaria Vaccine

Malaria continues to claim over 500,000 lives per year, mainly children in sub-Saharan Africa. 

Serum Institute has already produced 25 million doses of its new malaria vaccine, with a capacity of 100 million more awaiting launch in the coming months.

Rather than licensing production, Poonawalla says Serum will focus on exporting the malaria shot and other new vaccines globally.

Fighting Dengue

Another key target is dengue fever, a painful and potentially fatal mosquito-borne viral disease. 

Serum is testing a single-dose dengue vaccine developed by U.S. research. 

Late-stage trials are expected to be completed within three years.

While companies like Takeda already sell dengue vaccines, the need remains high—especially in outbreak hotspots like Brazil, which faces vaccine shortages.

With COVID manufacturing scaled back, Serum Institute is harnessing its formidable capacity to take on malaria, dengue, and other scourges. 

As the largest vaccine maker shifts priorities, the impact on global health could be immense.